Bolt Biotherapeutics(US:BOLT)2022-09-16 22:17Financial Status - Bolt Biotherapeutics had $2236 million in cash, cash equivalents, and marketable securities as of June 30, 2022[4] - The company's pipeline and operations are funded to achieve multiple milestones through 2025[14] BDC-1001 (HER2 Boltbody™ ISAC) - BDC-1001 is in Phase 1/2 clinical development targeting HER2-expressing solid tumors[15] - Early signs of disease control were noted in 13 out of 40 evaluable subjects[7] - The company anticipates completing monotherapy dose escalation and determining RP2D in the second half of 2022[14] - The company also anticipates completing Opdivo® combination dose escalation and determining RP2D in the second half of 2022[14] BDC-3042 (Dectin-2 agonist mAb) - IND-enabling studies for BDC-3042 are underway, with an IND filing and Phase 1 trial planned for 2023[12, 14] - BDC-3042 mediates anti-tumor activity, with a 33% mean tumor growth inhibition at 1 mg/kg and a 35% mean tumor growth inhibition with Pembrolizumab at 5 mg/kg in humanized mice bearing triple-negative breast tumors[31] Collaborations - The company is pursuing multiple ISAC programs with collaborators who fund research & development through initial proof-of-concept[3]